Suppr超能文献

同种异体输血是减瘤手术和热灌注化疗后围手术期预后较差及长期生存率降低的独立预测因素:936例病例的回顾。

Allogenic Blood Transfusion Is an Independent Predictor of Poorer Peri-operative Outcomes and Reduced Long-Term Survival after Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: a Review of 936 Cases.

作者信息

Saxena Akshat, Valle Sarah J, Liauw Winston, Morris David L

机构信息

UNSW Department of Surgery, St George Hospital, Kogarah, New South Wales, Australia.

出版信息

J Gastrointest Surg. 2017 Aug;21(8):1318-1327. doi: 10.1007/s11605-017-3444-8. Epub 2017 May 30.

Abstract

INTRODUCTION

There is a paucity of data on the impact of allogenic blood transfusion (ABT) on morbidity and survival outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC).

METHODS

Nine hundred and thirty-five consecutive CRS/HIPEC procedures were performed between 1996 and 2016 at a high-volume institution in Sydney, Australia. Of these, 337(36%) patients required massive ABT (MABT) (≥5 units). Peri-operative complications were graded according to the Clavien-Dindo classification. The association of concomitant MABT with 21 peri-operative outcomes and overall survival (OS) was assessed using univariate and multivariate analyses.

RESULTS

In-hospital mortality was 1.8%. Patients requiring MABT had more extensive disease as reflected by a higher peritoneal cancer index (≥17) (70 vs. 29%, p < 0.001) and longer operative times (≥9 h) (82 vs. 35%, p < 0.001). After accounting for confounding factors, MABT was associated with in-hospital mortality (relative risk (RR), 7.72; 95% confidence interval (CI), 1.35-10.11; p = 0.021) and grade III/IV morbidity (RR, 2.05; 95% CI, 1.42-2.95; p < 0.001). MABT was associated with an increased incidence of prolonged hospital stay (≥28 days) (RR, 1.86; 95% CI, 1.26-2.74; p = 0.002) and intensive care unit stay (≥4 days) (RR, 1.83; 95% CI, 1.24-2.70, p = 0.002). It was also associated with a significant OS in patients with colorectal cancer peritoneal carcinomatosis (RR 4.49; p < 0.001) and pseudomyxoma peritonei (RR, 4.37; p = 0.026), but not appendiceal cancer (p = 0.160).

CONCLUSION

MABT is an independent predictor for poorer peri-operative outcomes including in-hospital mortality and grade III/IV morbidity. It may also compromise long-term survival, particularly in patients with colorectal cancer peritoneal carcinomatosis.

摘要

引言

关于同种异体输血(ABT)对减瘤手术及热灌注化疗(CRS/HIPEC)后发病率和生存结局的影响,相关数据较少。

方法

1996年至2016年期间,在澳大利亚悉尼一家大型机构连续进行了935例CRS/HIPEC手术。其中,337例(36%)患者需要大量ABT(MABT)(≥5单位)。围手术期并发症根据Clavien-Dindo分类进行分级。采用单因素和多因素分析评估同时进行MABT与21种围手术期结局及总生存期(OS)之间的关联。

结果

住院死亡率为1.8%。需要MABT的患者疾病范围更广,表现为腹膜癌指数较高(≥17)(70%对29%,p<0.001)和手术时间更长(≥9小时)(82%对35%,p<0.001)。在考虑混杂因素后,MABT与住院死亡率(相对风险(RR),7.72;95%置信区间(CI),1.35 - 10.11;p = 0.021)和III/IV级发病率(RR,2.05;95% CI,1.42 - 2.95;p<0.001)相关。MABT与住院时间延长(≥28天)(RR,1.86;95% CI,1.26 - 2.74;p = 0.002)和重症监护病房住院时间延长(≥4天)(RR,1.83;95% CI,1.24 - 2.70,p = 0.002)的发生率增加相关。它还与结直肠癌腹膜转移癌患者(RR 4.49;p<0.001)和腹膜假黏液瘤患者(RR,4.37;p = 0.026)的显著OS相关,但与阑尾癌患者无关(p = 0.160)。

结论

MABT是围手术期结局较差的独立预测因素,包括住院死亡率和III/IV级发病率。它也可能影响长期生存,特别是在结直肠癌腹膜转移癌患者中。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验